• Berlin Cures, a clinical-stage biotechnology firm, advances innovative treatment aimed at combating Long COVID, currently impacting over 100 million people globally.
• Over 50% of patients in randomized placebo-controlled Phase-II-trial now recruited; no issues regarding safety observed.
• Berlin Cures innovative platform develops novel aptamer-based drugs to neutralize pathogenic functional autoantibodies, targeting diseases.

BERLIN, GERMANY – Media OutReach Newswire – 4 March 2024 – Berlin Cures, a clinical-stage biotechnology company, has reached a significant milestone in its Europe-wide clinical trial for Long COVID, effectively enrolling over 50% of the targeted 114 patients and expanding the study’s inclusion criteria. The trial is investigating the efficacy of BC 007, the company’s pioneering drug candidate designed to neutralize functional autoantibodies (fAABs), which play a key role in the persistence of Long COVID symptoms.

The study is actively progressing across 12 trial centers in Finland, Germany, Austria, Switzerland, and Spain, exemplifying the collaborative effort to address Long COVID, which has developed into a significant global health issue. Progress is strong and another seven centers are set to join soon. Anticipated results in autumn 2024 will pave the way for the next development stage, with Berlin Cures currently seeking additional funding to complete Phase II and initiate the crucial Phase III study necessary for regulatory approval.

“Long COVID has impacted the lives of over 100 million people globally, altering the day-to-day existence of countless individuals,” states Oliver von Stein, CEO of Berlin Cures. “Our mission with BC 007 is not just to treat a virus’s lingering effects but to restore the quality of life for those affected. By harnessing the power of innovative science, we are on the cusp of a breakthrough that could return health and vitality to millions. The progress of our clinical trial across Europe is a beacon of hope and a testament to what we can achieve through collaboration and dedication.”

As a biotech company focused on neutralizing fAABs, Berlin Cures stands at the forefront of developing innovative treatments for a variety of autoimmune diseases, including Long COVID, heart failure, glaucoma, and many others. Its drug candidate, BC 007, represents a promising solution by targeting harmful fAABs implicated in a range of autoimmune conditions such as Long COVID.

The ongoing Phase II clinical trial in Long COVID seeks to deliver conclusive and reliable results on the drug’s effectiveness and safety for patients. The company anticipates a positive outcome, which will pave the way to proceed with a larger Phase III study, crucial for BC 007’s approval.

BC 007 Could Potentially Cure Long COVID for Many
Current estimates indicate that functional autoantibodies (fAABs) are detectable in blood tests in about 40% of all Long COVID patients. Functional autoantibodies are a specific type of autoantibody that can develop as an immune response following infections, mistakenly target the body’s tissues or cells. This interaction can lead to autoimmune diseases. Unlike normal antibodies that protect against infections, fAABs disrupt normal functions by binding to cell receptors or other proteins, often imitating or blocking natural signals needed for healthy cell functions. This disruption can result in a variety of autoimmune diseases, depending on the target of the autoantibodies and the role of the targeted tissue in the body.

“The presence of fAABs in such a large portion of patients highlights the potential of BC 007 to combat the underlying cause of Long COVID symptoms in a significant group of affected individuals. We are convinced of BC 007’s therapeutic potential and are actively seeking support to prepare for a larger Phase III study,” adds Oliver von Stein. “Our commitment to finding a cure for diseases caused by fAABs remains steadfast, supported by private funding since our inception.”

Versatile Platform Technology Targeting Multiple Medical Conditions
The potential of BC 007 extends beyond treating a single disease, making it a so-called platform technology. By neutralizing fAABs, BC 007 could potentially act against many fAAB-associated diseases.

Built on more than two decades of fAAB-research, Berlin Cures has advanced BC 007 into clinical trials. This journey has demonstrated efficacy in Phase I studies with fAAB-positive volunteers and in a Phase IIa trial with heart failure patients, showing significant long-term benefits. Preclinical and clinical results with BC 007 have shown effective and lasting neutralization of fAABs after treatment. Moreover, BC 007 has proven to be safe and well-tolerated. With the ongoing Phase II trial focusing on Long COVID, Berlin Cures continues to seek additional investments and partnerships to advance this groundbreaking opportunity.

Hashtag: #BerlinCures

The issuer is solely responsible for the content of this announcement.

About Berlin Cures:

The Berlin Cures team has dedicated over two decades to the research of functional autoantibodies (fAABs) and has successfully identified a molecule capable of effectively neutralizing these. Promising preclinical results have been observed for BC 007. It was found effective in fAAB-positive healthy volunteers during the Phase I study and in heart failure patients in a Phase IIa trial, where it demonstrated long-term autoantibody neutralization after a single dose and significant improvement in cardiac function, with no spontaneous disappearance of autoantibodies in untreated patients. Its potential against Long COVID is indicated by lab data generated using sera from Long COVID patients, and four case studies. By tackling the root cause of fAAB-associated diseases with this unique biotechnology, Berlin Cures emerges as one of the pioneering entities committed to addressing this critical issue at its core.

Since June 2023, Berlin Cures has been absolving a Phase II clinical trial with BC 007 in the indication Long COVID, an acute and escalating global health problem, to obtain meaningful and robust results on efficacy and tolerability of BC 007 with patients suffering from Long COVID.

Leading the Two Golden Tracks of Pneumonia Vaccine and Rabies Vaccines

HONG KONG SAR – Media OutReach Newswire – 4 March 2024 – AIM Vaccine Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the company has made significant progress in the research and development of its Pneumonia vaccine and Rabies vaccine products. The launch of these new products is expected to accelerate, providing significant momentum for the company’s future revenue growth. The Company has initiated Phase II clinical trials for its Tetravalent meningococcal conjugate vaccine (MCV4), while the clinical trials for the Group’s diphtheria, tetanus and acellular pertussis – HIB combined vaccine is also progressing rapidly.

According to the preliminary performance forecast for the 2023 , assuming that the sales revenue remains relatively stable compared to 2022, the company has made significant provisions for impairment of intangible assets and goodwill, as well as increased research and development expenses due to the third-phase clinical trials of its five major core products and the changing landscape of the COVID-19 pandemic. As a result, the performance for the year 2023 is expected to be a loss. However, it is anticipated that with the concentrated launch of several heavyweight new products by the company, AIM Vaccine is poised for a strong comeback

AIM Vaccine is strategically developing its portfolio of Pneumonia vaccine products by continuously innovating and rapidly advancing iterative upgrades through research and development. Among them, the 13-valent pneumonia conjugate vaccine has completed on-site work for Phase III clinical trial and has submitted a pre-application for marketing. the 23-valent pneumonia polysaccharide vaccine has also completed Phase III clinical trial and is expected to apply for marketing registration in 2024. the 20-valent pneumonia conjugate vaccine has submitted a pre-application for clinical trials; while the 24-valent pneumonia conjugate vaccine, which is being simultaneously developed globally for the first time, has completed preclinical research.

According to the classification of the World Health Organization, pneumococcal disease is one of the diseases requiring “very high priority” use of vaccines for prevention. The 13-valent pneumonia conjugate vaccine approved in China only covers those under 6 years old. The market for those over 6 years old is still blank. China Insights Industry Consultancy Limited, an industry consultant, predicts that the market size of this vaccine in China is expected to exceed RMB20 billion by 2030, indicating tremendous market potential. In addition, the estimated penetration rate of the 13-valent pneumonia conjugate vaccine in the approved age group in China is 25.9%, while the penetration rate in the corresponding age group in the United States exceeds 80%, indicating that there is still significant room for growth in the Chinese market. It is estimated that the global underserved demand for the 13-valent pneumonia conjugate vaccines is as high as 180 million doses. However, currently only three companies have been approved to supply them globally. After the launch of its 13-valent pneumonia conjugate vaccine, the Group is expected to become an important supplier in the market.

The Group’s strategic positioning of its rabies vaccine products has also achieved exciting progress. As the second largest supplier of rabies vaccine globally, the Group has expedited the development of iterative rabies series vaccines, in particular: The on-site work of the phase III clinical trial of iterative serum-free rabies vaccine has been completed, and various preparatory work for the new drug application is underway, which is planned to be completed in 2024; The pre-application for clinical trial for the novel-process human diploid rabies vaccine is expected to be submitted in the first half of 2024; 3. the iterative mRNA rabies vaccine is the first non-COVID-19 mRNA vaccine candidate accepted by relevant authorities in China.

To date, there is no serum-free rabies vaccine approved for launch in the global market. The novel-process human diploid rabies vaccine developed by the Group became the first to break through the technical bottleneck of low virus titer and small yield in the traditional process, with optimized and innovated purification process, which has notably improved product quality and safety as compared with similar marketed products in China, and has the production capacity for large-scale commercialization.

Based on the performance forecast and the progress in product development, AIM Vaccine’s investment in research and development is gradually paying off. The company’s revenue and operations are stable and improving, which will help the company better seize market opportunities. At the same time, AIM Vaccine adheres to its development strategy and layout of major single products, large production capacity, and strong commercialization capabilities. Leveraging its top-class vaccine development platform technology and internal research and development team, the company fully meets the market demand for iterative upgraded vaccines. This helps achieve new productive forces in the industry, leads international industry innovation, and contributes to the establishment of a robust public health system and the comprehensive implementation of the Healthy China strategy.
Hashtag: #AIMVaccine

The issuer is solely responsible for the content of this announcement.

About AIM Vaccine Co., Ltd.

AIM Vaccine (stock code: 06660) is committed to manufacturing conscientious vaccines and promoting the health of the people. It is the second-largest vaccine group in China and the largest private-sector vaccine group, with a complete industry chain. AIM Vaccine is a leading company in the Chinese vaccine industry and one of the top players in the mRNA vaccine field. As one of the most strictly regulated industries in the country, China has over 40 vaccine production qualifications nationwide. Currently, AIM Vaccine owns four wholly-owned licensed vaccine production companies and three vaccine research institutes. It is one of the only two human vaccine companies in China with strategic resources such as P3 laboratories. AIM Vaccine is also the world’s largest manufacturer of hepatitis B vaccines and the second-largest manufacturer of rabies vaccines globally.

AIM Vaccine has a portfolio of eight commercialized vaccines and 23 vaccines under development, covering the top ten vaccine varieties globally. Its commercialized products have maintained a leading market position for a long time, with sales covering all 31 provinces, municipalities, and autonomous regions in China, reaching over 2,000 district and county-level disease control centers.

KAOHSIUNG, TAIWAN – Media OutReach Newswire – 4 March 2024 – Headed by Deputy Mayor Lo Ta-sheng, the Kaohsiung delegation to KUMAMOTO Industrial Revitalization EXPO 2024 and for a fact-finding tour of Kyushu has wound up a hugely rewarding journey. Over the course of the two-day expo, the Kaohsiung Pavilion hosted 830 international visitors, talked with 50 potential buyers, and garnered orders estimated at US$1,140,000. Above all, the visit proved a great success in arousing Japanese businesses’ interest in the port city of Kaohsiung. The Kaohsiung City Government’s efforts towards soliciting businesses and investments have indeed paid off in the form of a boost to international reputation.

Deputy Mayor Lo said the latest expo was intended mainly to showcase Kumamoto’s resilience and extraordinary recovery in the wake of the 2016 earthquake and the flooding in July 2020. Above all, the welcome advent of Taiwan Semiconductor Manufacturing Co., Ltd. (TSMC) gave a further boost to its revitalization. Kaohsiung and Kumamoto are both semiconductor hubs: the former enjoys an edge in wafer foundry and packaging and testing while the latter excels in materials and equipment. To promote closer collaboration between the two cities, Lo explained, the Kaohsiung delegation comprised four local semiconductor companies: 4DMEN Technology Co., Ltd., Taiwan Valqua Engineering International Ltd., Gongin Precision Ind. Co., Ltd., and Advanced Echem Materials Co., Ltd. In addition to enhancing their brand visibility, they were excited to learn more about Kumamoto’s semiconductor needs and broaden their business reach accordingly.

Moreover, Shinya Iwashita, Chief Executive Officer of Tsuruya Department Store subsidiary Amanatsu Royal Co., Ltd., visited the Kaohsiung Pavilion at the invitation of the Kaohsiung City Government. After consultations with MAYUSHAN FOOD Co., Ltd., Joywell Cake Store Co., Ltd., and LE PONT, he lauded their dedication to R&D and impressive array of food products placing emphasis on both health and flavor. Tsuruya Department Store is optimistic about the potential of these delicacies and keen to usher them into the Japanese market at an early date.

Alongside its attendance at the Kumamoto Expo, the Kaohsiung City Government organized an investment promotion seminar at the startup hub Growth 1 in Fukuoka. The event attracted over 40 visitors from more than 10 startups in such fields as IOT, smart medical devices, and green energy. What followed was a string of lively discussions about possible cooperation. Hori Hironobu, director of the Fukuoka City Government’s Business Startup & Investment Promotion Department, said the city’s designation as a National Strategic Special Zone for startups in 2012 has made it an irresistible magnet attracting global startups to invest. Fukuoka looks forward to working with Kaohsiung to create a cross-border ecosystem that accommodates the startups of both Taiwan and Japan.

Liao Tai-hsiang, director-general of the Economic Development Bureau, Kaohsiung City Government, said that Fukuoka is home to many promising international startups while Kaohsiung boasts Asia’s New Bay 2.0 Park as well as multiple startup hubs and incubation centers. Given the two’s complementary development paths, there is ample room for bilateral cooperation in R&D, talent cultivation, startup interconnections, and industry exchanges, thereby providing their respective startups with fresh momentum for innovation. Japan’s startups are welcome to come to Kaohsiung and the city government is ready to provide them with one-stop services and whatever other assistance is needed.

The Kaohsiung delegation also visited the Fukuoka Hydrogen Station, the world’s first such facility offering energy sourced from sewage treatment. As a major industrial city committed to achieving net zero in 2050, Kaohsiung is keen to promote carbon reduction, stay up to date with the latest in green energy, and ultimately attain sustainable development. In Fukuoka, the delegation also called at the Kyushu Bureau of Economy, Trade and Industry and Kyushu University to discuss bolstering exchanges in the semiconductor industry and its talent. The consensus is for Kaohsiung and Kyushu to strengthen academic and technological cooperation, engage in closer industry-academic collaboration, and extend support for education and research, thereby making semiconductor companies of both sides more competitive going forward.

Hashtag: #Kaohsiung

The issuer is solely responsible for the content of this announcement.

BANGKOK, THAILAND – Media OutReach Newswire – 4 March 2024 – Amari Pattaya, nestled at the serene northern edge of Pattaya Bay, Thailand, is thrilled to unveil its latest offering – the immersive Beach Lawn Glamping experience. Tailored for families, couples, and groups of friends, this captivating event takes place every Saturday on the resort’s green and lush lawn, set against the picturesque backdrop of Pattaya Bay’s mesmerising sunset. Just steps away lies a serene stretch of one of Thailand’s most popular beaches, adorned with golden sands and gently lapping waves, creating a personal tropical paradise. Entry is free, with both resort guests and locals invited to join the unforgettable evening, featuring delicious food and drink, arts and crafts, outdoor games, live music and welcoming hospitality amidst the balmy Thai evening air.

From 17:00 to 20:00, attendees are treated to a culinary journey featuring a delightful selection of meticulously crafted dishes and refreshing beverages, celebrating the essence of coastal living. Beach Lawn Glamping is more than just a gastronomic delight; it’s a sanctuary for creativity and exploration.

Starting from 17:30 to 20:00, guests of all ages can unleash their imagination and artistic flair through engaging arts and crafts activities, where every creation becomes a testament to the beauty of self-expression. As live music fills the air with rhythmic melodies from 18:00 to 20:00, attendees find themselves swept away by the charm of the occasion, dancing beneath the stars and forging connections that transcend language and culture.

Whether savouring exquisite flavours, indulging in creative pursuits, or losing themselves in the enchanting melodies, Beach Lawn Glamping promises an unforgettable experience for all who attend.

A slice of paradise on the pristine shores of Pattaya Bay, away from the hustle-and-bustle, Amari Pattaya is a luxurious, family-friendly resort, with spaces thoughtfully designed for that comforting home-from-home experience, with sand, sea and surf provided aplenty. With unparalleled views of the azure waters, golden sands and lush greenery, this iconic, tranquil resort embodies the essence of Thai hospitality. From its elegantly appointed rooms and suites to its world-class amenities, every aspect of Amari Pattaya is designed to offer guests an unforgettable stay. Whether lounging by the infinity pool, rejuvenating at the Breeze Spa, or savouring delectable cuisine at its signature restaurants, guests are treated to a truly unforgettable retreat and invited to discover the beauty of this Thai coastal paradise. Younger group members will be well-entertained with a comprehensive Kids Club, large pool complete with fountains and slides, and play park. Making family trips, multi-generational travel, or travelling with a group, easier than ever, Amari Pattaya offers 2-3 bedroom Amari Suites. The vibrant buzz of Pattaya’s modern city malls are also nearby for those looking to add shopping and exploration into their trip.

Prices at Amari Pattaya start from 3,250 THB per night (approximately GBP £71), based on two sharing a Deluxe room on a room only basis. Stay before 30^th June 2024 and receive an exclusive 20% discount on food and beverages from the à la carte menu, when booked online using the ‘Web Exclusive Package’. For bookings, please visit: https://www.amari.com/pattaya/special-offers

For more information on Amari Pattaya, please visit: www.amari.com/pattaya

For more information about Amari, please visit www.amari.com

For more information about ONYX Hospitality Group, please visit www.onyx-hospitality.com

Follow us on Instagram: https://www.instagram.com/onyxhospitalitygroup/

Follow us on LinkedIn: https://www.linkedin.com/company/onyx-hospitality-group/

Hashtag: #AmariPattaya

The issuer is solely responsible for the content of this announcement.